Nutrigenetics and CVD: What does the future hold?

Proceedings of the Nutrition Society

Volumn 67, Issue 2, 2008, Pages 206-213

  Lovegrove, Julie A ^a   Gitau, Rachel ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

ApoE, apoAI and PPAR polymorphisms; CVD risk; Dietary fat; Nutrigenetics

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DIETARY INTAKE; FAT INTAKE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN GENOME; MEDICAL RESEARCH; NUTRIGENOMICS; OBESITY; OUTCOME ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; DIET; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPID METABOLISM; NUTRIGENOMICS; NUTRITION PHYSIOLOGY; POLYMORPHISM, GENETIC; PPAR GAMMA; RISK FACTORS; VARIATION (GENETICS);

EID: 42149108476     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665108007040     Document Type: Conference Paper

References (64)

1. Allender S, Peto V, Scarborough P, Boxer A & Rayner M (2007) Coronary Heart Disease Statistics 2007. London: British Heart Foundation.
2. British Heart Foundation (2003) Coronary heart disease statistics. http://dphpc.ox.ac.uk/bhfhprg/stats/2003/
3. Kaput J & Rodriguez RL (2004) Nutritional genomics: the next frontier in the postgenomic era. Physiol Genomics 16, 166-177.
4. Ordovas JM & Mooser V (2004) Nutrigenomics and nutrigenetics. Curr Opin Lipidol 15, 101-108.
5. Corthesy-Theulaz I, den Dunnen JT, Ferre P, Geurts JM, Muller M, van Belzen N & van Ommen B (2005) Nutrigenomics: the impact of biomics technology on nutrition research. Ann Nutr Metab 49, 355-365.
6. McVean G, Spencer C & Chaix R (2005) Perspectives on human genetic variation from the HapMap project. PLoS Genet 1, e54.
7. Hinds D, Stuve L, Nilsen GB, Halperin E, Eskin E, Ballinger D, Frazer KA & Cox DR (2005) Whole -genome patterns of common DNA variation in three human populations. Science 307, 1052-1053.
8. Frayling TM, Timpson NJ, Weedon MN et al. (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316, 889-894.
9. Stratakis CA, Lafferty A, Taymans SE, Gafni RI, Meck JM & Blancato J (2000) Anisomastia associated with interstitial duplication of chromosome 16, mental retardation, obesity, dysmorphic facies, and digital anomalies: molecular mapping of a new syndrome by fluorescent in situ hybridization and microsatellites to 16q13 (D16S419-D16S503). J Clin Endocrinol Metab 85, 3396-3401.
10. Mutch DM, Wahli W & Williamson G (2005) Nutrigenomics and nutrigenetics: the emerging faces of nutrition. FASEB J 19, 1602-1616.
11. Bucher HC, Hengstler P, Schindler C & Meier G (2002) N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112, 298-304.
12. Burr L, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC & Deadman NM (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet ii, 757-761.
13. Kris-Etherton P, Harris W & Appel L (2003) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 23, E31-E42.
14. Minihane AM, Khan S, Leigh-Firbank EC, Talmud P, Wright JW, Murphy MC, Griffin BA & Williams CM (2000) ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 20, 1990-1997.
15. Lovegrove JA, Lovegrove SS, Lesauvage SV, Brady LM, Saini N, Minihane AM & Williams CM (2004) Moderate fish-oil supplementation reverses low-platelet, long-chain n-3 polyunsaturated fatty acid status and reduces plasma triacylglycerol concentrations in British Indo-Asians. Am J Clin Nutr 79, 974-982.
16. Brady LM, Lovegrove SS, Lesauvage SV, Gower BA, Minihane AM, Williams CM & Lovegrove JA (2004) Increased n-6 polyunsaturated fatty acids do not attenuate the effects of long-chain n-3 polyunsaturated fatty acids on insulin sensitivity or triacylglycerol reduction in Indian Asians. Am J Clin Nutr 79, 983-991.
17. Huang Y, Ji ZS, Brecht WJ, Rall SC Jr, Taylor JM & Mahley RW (1999) Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. Arterioscler Thromb Vasc Biol 19, 2952-2959.
18. Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630.
19. Minihane AM, Jofre-Monseny L, Olano-Martin E & Rimbach GH (2007) Apolipoprotein E genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc Nutr Soc 66, 183-197.
20. Rall SC Jr, Weisgraber KH & Mahley RW (1982) Human apolipoprotein E (). The complete amino acid sequence. J Biol Chem 257, 4171-4178.
21. Weisgraber KH (1990) Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res 31, 1503-1511.
22. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE & Stroehla BC (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155, 487-495.
23. Singh P, Singh M & Mastana S (2006) ApoE distribution in world populations with new data from India and the UK. Ann Hum Biol 33, 297-308.
24. Song Y, Stampfer MJ & Liu S (2004) Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141, 137-147.
25. Minihane AM, Jofre-Monseny L, Olano-Martin E & Rimbach G (2007) ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc Nutr Soc 66, 183-197.
26. Sarkkinen E, Korhonen M, Erkkila A, Ebeling T & Uusitupa M (1998) Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. Am J Clin Nutr 68, 1215-1222.
27. Miettinen TA, Gylling H, Vanhanen H & Ollus A (1992) Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apoprotein E phenotypes. Arterioscler Thromb 12, 1044-1052.
28. Lehtimaki T, Moilanen T, Solakivi T, Laippala P & Ehnholm C (1992) Cholesterol-rich diet induced changes in plasma lipids in relation to apolipoprotein E phenotype in healthy students. Ann Med 24, 61-66.
29. Friedlander Y, Berry EM, Eisenberg S, Stein Y & Leitersdorf E (1995) Plasma lipids and lipoproteins response to a dietary challenge: analysis of four candidate genes. Clin Genet 47, 1-12.
30. Tso TK, Park S, Tsai YH, Williams G & Snook JT (1998) Effect of apolipoprotein E polymorphism on serum lipoprotein response to saturated fatty acids. Lipids 33, 139-148.
31. Dreon DM, Fernstrom HA, Miller B & Krauss RM (1995) Apolipoprotein E isoform phenotype and LDL subclass response to a reduced-fat diet. Arterioscler Thromb Vasc Biol 15, 105-111.
32. Schaefer EJ, Lamon-Fava S, Ausman LM, Ordovas JM, Clevidence BA, Judd JT, Goldin BR, Woods M, Gorbach S & Lichtenstein AH (1997) Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets. Am J Clin Nutr 65, 823-830.
33. Lopez-Miranda J, Ordovas JM, Mata P, Lichtenstein AH, Clevidence B, Judd JT & Schaefer EJ (1994) Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. J Lipid Res 35, 1965-1975.
34. Tikkanen MJ, Huttunen JK, Ehnholm C & Pietinen P (1990) Apolipoprotein E4 homozygosity predisposes to serum cholesterol elevation during high fat diet. Arteriosclerosis 10, 285-288.
35. Manttari M, Koskinen P, Ehnholm C, Huttunen JK & Manninen V (1991) Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention. Metabolism 40, 217-221.
36. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, Contois JH, Li Z, Rasmussen H, McNamara JR & Ordovas JM (1995) Efficacy of a National Cholesterol Education Program Step 2 diet in normolipidemic and hypercholesterolemic middleaged and elderly men and women. Arterioscler Thromb Vasc Biol 15, 1079-1085.
37. Masson LF, McNeill G & Avenell A (2003) Genetic variation and the lipid response to dietary intervention: a systematic review. Am J Clin Nutr 77, 1098-1111.
38. Couture P, Archer WR, Lamarche B, Landry N, Deriaz O, Corneau L, Bergeron J & Bergeron N (2003) Influences of apolipoprotein E polymorphism on the response of plasma lipids to the ad libitum consumption of a high-carbohydrate diet compared with a high-monounsaturated fatty acid diet. Metabolism 52, 1454-1459.
39. Moreno JA, Perez-Jimenez F, Marin C, Gomez P, Perez-Martinez P, Moreno R, et al. (2004) The effect of dietary fat on LDL size is influenced by apolipoprotein E genotype in healthy subjects. J Nutr 134, 2517-2522.
40. Ordovas JM (2006) Genetic interactions with diet influence the risk of cardiovascular disease. Am J Clin Nutr 83, 443S-446S.
41. Wilson PW, Abbott RD & Castelli WP (1988) High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8, 737-741.
42. Ordovas JM, Corella D, Cupples LA, Demissie S, Kelleher A, Coltell O, Wilson PWF, Schaefer EJ & Tucker K (2002) Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. Am J Clin Nutr 75, 38-46.
43. Auwerx J (1999) PPARgamma, the ultimate thrifty gene. Diabetologia 42, 1033-1049.
44. Rosen ED & Spiegelman BM (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276, 37731-37734.
45. Cecil JE, Watt P, Palmer CN & Hetherington M (2006) Energy balance and food intake: the role of PPARgamma gene polymorphisms. Physiol Behav 88, 227-233.
46. Memisoglu A, Hu FB, Hankinson SE, Liu S, Meigs JB, Altshuler DM, Hunter DJ & Manson JE (2003) Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARgamma gene and type 2 diabetes. Diabetes Care 26, 2915-2917.
47. Gonzalez Sanchez JL, Serrano Rios M, Fernandez Perez C, Laakso M & Martinez Larrad MT (2002) Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 147, 495-501.
48. Frederiksen L, Brodbaek K, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S & Urhammer SA (2002) Studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 87, 3989-3992.
49. Altshuler D, Hirschhorn JN, Klannemark M et al. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26, 76-80.
50. Soriguer F, Morcillo S, Cardona F, Rojo-Martinez G, de la Cruz Almaraz M, de la Soledad Ruiz de Adana M, Olveira G, Tinahones F & Esteva I (2006) Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr 136, 2325-2330.
51. Stumvoll M, Wahl HG, Loblein K, Becker R, Machicao F, Jacob S & Häring H (2001) Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 50, 876-881.
52. Vaccaro O, Mancini FP, Ruffa G et al. (2002) Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) gamma2 gene in healthy individuals. Clin Endocrinol (Oxf) 57, 481-486.
53. Memisoglu A, Hu FB, Hankinson SE, Manson JE, De Vivo I, Willett WC & Hunter DJ (2003) Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 12, 2923-2929.
54. Robitaille J, Despres JP, Perusse L & Vohl MC (2003) The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin Genet 63, 109-116.
55. Luan J, Browne PO, Harding AH, Halsall DJ, O'Rahilly S, Chatterjee VK & Wareham NJ (2001) Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50, 686-689.
56. Lindi VI, Uusitupa MI, Lindstrom J et al. (2002) Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51, 2581-2586.
57. Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE & Shuldiner AR (2001) Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 50, 2172-2176.
58. Poirier O, Nicaud V, Cambien F & Tiret L (2000) The Pro12Ala polymorphism in the peroxisome proliferatoractivated receptor gamma2 gene is not associated with postprandial responses to glucose or fat tolerance tests in young healthy subjects: the European Atherosclerosis Research Study II. J Mol Med 78, 346-351.
59. Lindi V, Schwab U, Louheranta A et al. (2003) Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation. Mol Genet Metab 79, 52-60.
60. Olefsky JM & Saltiel AR (2000) PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11, 362-368.
61. Cogent (2003) Congent syndicated genomics attitudes and trends: consumers. http://www.cogentresearch.com/products/CGAT%20Brochurepdf
62. Henderson L, Gregory J & Swan G (2003) The National Diet and Nutrition Survey: Adults Aged 19-64 Years. London: The Stationery Office.
63. Cannon G & Leitzmann C (2005) The new nutrition Science project. Public Health Nutr 8, 673-694.
64. McCluskey S, Baker D, Percy D, Lewis P & Middleton E (2007) Reductions in cardiovascular risk in association with population screening: a 10-year longitudinal study. J Public Health (Oxf) 29, 379-387.